Article
Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting.
Journal of cancer research and clinical oncology - 1 Sept 2023
Kraskowski Oliver, Stratmann Jan A, Wiesweg Marcel, Eberhardt Wilfried, Metzenmacher Martin, Schmid Kurt W, Herold Thomas, Schildhaus Hans-Ulrich, Darwiche Kaid, Aigner Clemens, Stuschke Martin, Laue Katharina, Zaun Gregor, Kasper Stefan, Hense Jörg, Sebastian Martin, Schuler Martin, Pogorzelski Michael
Abstract excerpt
PURPOSE: EGFR tyrosine kinase inhibitor (TKI) therapy in EGFR-mutated lung cancer is limited by acquired resistance. In half of the patients treated with first/second-generation (1st/2nd gen) TKI, resistance is associated with EGFR p.T790M mutation. Sequential treatment with osimertinib is highly active in such patients. Currently, there is no approved targeted second-line option for patients receiving first-line...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.